Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J De Schepper

Showing results (121-130 of 149) with videos related to

Pageof 15
Sort By:
European Journal of Clinical Pharmacology|July 6, 2000
Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humansM Depré, E Ehrich, A Van Hecken, et al.
The Journal of Clinical Endocrinology and Metabolism|May 14, 1999
Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age: results over 6 yearsF de Zegher, M V Du Caju, C Heinrichs, et al.
European Journal of Clinical Pharmacology|January 1, 1994
Plasma concentrations and effect on testosterone metabolism after single doses of MK-0434, a steroid 5 alpha-reductase inhibitor, in healthy subjectsA Van Hecken, M Depré, J I Schwartz, et al.
European Journal of Clinical Pharmacology|January 1, 1992
Plasma drug profiles and tolerability of MK-571 (L-660,711), a leukotriene D4 receptor antagonist, in manM Depré, D J Margolskee, J Y Hsieh, et al.
The Journal of Clinical Endocrinology and Metabolism|September 13, 2003
Late or delayed induced or spontaneous puberty in girls with Turner syndrome treated with growth hormone does not affect final heightG Massa, C Heinrichs, S Verlinde, et al.
Clinical Pharmacology and Therapeutics|July 1, 1994
Pharmacokinetics and pharmacodynamics of multiple oral doses of MK-0591, a 5-lipoxygenase-activating protein inhibitorM Depré, B Friedman, A Van Hecken, et al.
Journal of Clinical Pharmacology|September 3, 1999
Effect of multiple doses of montelukast, a CysLT1 receptor antagonist, on digoxin pharmacokinetics in healthy volunteersM Depré, A Van Hecken, R Verbesselt, et al.
European Journal of Endocrinology|July 14, 2004
Prevalence and demographic features of childhood growth hormone deficiency in Belgium during the period 1986-2001M Thomas, G Massa, M Craen, et al.
The Journal of Clinical Investigation|September 1, 1984
Plasma mevalonate as a measure of cholesterol synthesis in manT S Parker, D J McNamara, C D Brown, et al.
Hormone Research|August 7, 2004
Health and psychosocial status of patients with turner syndrome after transition to adulthood: the Belgian experienceF Verlinde, G Massa, K Lagrou, et al.
Pageof 15

Showing results (121-130 of 149) with videos related to

Sort By:
Pageof 15
European Journal of Clinical Pharmacology|July 6, 2000
Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humansM Depré, E Ehrich, A Van Hecken, et al.
The Journal of Clinical Endocrinology and Metabolism|May 14, 1999
Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age: results over 6 yearsF de Zegher, M V Du Caju, C Heinrichs, et al.
European Journal of Clinical Pharmacology|January 1, 1994
Plasma concentrations and effect on testosterone metabolism after single doses of MK-0434, a steroid 5 alpha-reductase inhibitor, in healthy subjectsA Van Hecken, M Depré, J I Schwartz, et al.
European Journal of Clinical Pharmacology|January 1, 1992
Plasma drug profiles and tolerability of MK-571 (L-660,711), a leukotriene D4 receptor antagonist, in manM Depré, D J Margolskee, J Y Hsieh, et al.
The Journal of Clinical Endocrinology and Metabolism|September 13, 2003
Late or delayed induced or spontaneous puberty in girls with Turner syndrome treated with growth hormone does not affect final heightG Massa, C Heinrichs, S Verlinde, et al.
Clinical Pharmacology and Therapeutics|July 1, 1994
Pharmacokinetics and pharmacodynamics of multiple oral doses of MK-0591, a 5-lipoxygenase-activating protein inhibitorM Depré, B Friedman, A Van Hecken, et al.
Journal of Clinical Pharmacology|September 3, 1999
Effect of multiple doses of montelukast, a CysLT1 receptor antagonist, on digoxin pharmacokinetics in healthy volunteersM Depré, A Van Hecken, R Verbesselt, et al.
European Journal of Endocrinology|July 14, 2004
Prevalence and demographic features of childhood growth hormone deficiency in Belgium during the period 1986-2001M Thomas, G Massa, M Craen, et al.
The Journal of Clinical Investigation|September 1, 1984
Plasma mevalonate as a measure of cholesterol synthesis in manT S Parker, D J McNamara, C D Brown, et al.
Hormone Research|August 7, 2004
Health and psychosocial status of patients with turner syndrome after transition to adulthood: the Belgian experienceF Verlinde, G Massa, K Lagrou, et al.
Pageof 15